199 related articles for article (PubMed ID: 31422587)
1. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
Li Y; Chen J
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
3. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
4. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
6. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
[TBL] [Abstract][Full Text] [Related]
8. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
Dong J; Li B; Zhou Q; Huang D
J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
[TBL] [Abstract][Full Text] [Related]
9. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 co-location: A novel biomarker for immunotherapy response in non-small cell lung cancer.
Diao X; Guo C; Li S
Thorac Cancer; 2022 Jun; 13(11):1545-1547. PubMed ID: 35481695
[No Abstract] [Full Text] [Related]
13. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
Mansfield AS; Dong H
Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Passiglia F; Commendatore O; Vitali M; Conca R
Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
Rossi S; Castello A; Toschi L; Lopci E
Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
[TBL] [Abstract][Full Text] [Related]
16. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
17. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
18. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy.
Li M; Gan L; Song A; Xue J; Lu Y
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):323-330. PubMed ID: 30826426
[TBL] [Abstract][Full Text] [Related]
19. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]